What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally

2 hours ago 1

Jonathan Ponciano, The Motley Fool

Sun, January 11, 2026 astatine 5:38 PM CST 5 min read

An AnaptysBio manager sold 3,900 shares of the banal connected Dec. 23 for a full worth of $193,342.50.
The merchantability represented 28.82% of J. Anthony Ware's nonstop holdings, arsenic reported, reducing his presumption from 13,530 to 9,630 shares.
All shares sold were held directly, with nary engagement from indirect entities oregon derivative instruments.
These 10 stocks could mint the adjacent question of millionaires ›

On Dec. 23, AnaptysBio (NASDAQ:ANAB) Director J. Anthony Ware executed an open-market merchantability of 3,900 shares for a transaction worth of $193,342.50, representing 28.82% of his nonstop holdings, according to an SEC Form 4 filing.

Metric

Value

Shares sold (direct)	3,900
Transaction value	$193,342.50
Post-transaction shares (direct)	9,630
Post-transaction worth (direct ownership)	$481,885.20

Transaction worth based connected SEC Form 4 reported terms ($49.58); post-transaction worth based connected the Dec. 23 marketplace adjacent ($50.04).

How worldly was the simplification successful nonstop ownership from this transaction?
The merchantability reduced Ware's nonstop holdings by 28.82%, leaving him with 9,630 shares, a important accommodation successful vulnerability wrong a azygous event.
Did this merchantability impact immoderate indirect holdings oregon peculiar entity structures?
No; each shares were held and sold directly, with nary indirect ownership via trusts oregon related entities, emphasizing a idiosyncratic portfolio decision.
What discourse exists for this being Ware’s archetypal open-market merchantability astatine AnaptysBio?
This is the lone open-market merchantability successful the reporting period; the preceding 5 filings were administrative successful nature. This commercialized is simply a notable displacement from humanities activity.
How does the transaction’s timing subordinate to the company’s show and valuation setup?
The merchantability occurred with the banal priced astatine $50.04 astatine marketplace close, aft a 264.63% one-year instrumentality arsenic of Dec. 23, suggesting Ware acted during a play of elevated stock terms and realized gains.

Metric

Value

Price (as of marketplace adjacent 12/23/25)	$49.58
Market capitalization	$1.39 billion
Revenue (TTM)	$169.47 million
1-year terms change	264.63%

* 1-year show calculated utilizing Dec. 23, 2025 arsenic the notation date.

AnaptysBio develops therapeutic antibodies targeting inflammation and immuno-oncology, with cardinal programs including imsidolimab (IL-36R inhibitor), rosnilimab (anti-PD-1 agonist), and ANB032 (anti-BTLA modulator).
The institution generates gross done proprietary objective pipeline advancement and strategical collaborations, including licensing agreements with large pharmaceutical partners specified arsenic GlaxoSmithKline and Bristol-Myers Squibb.
It develops therapeutic antibodies for dermatological and immunological diseases and advances programs to preclinical and objective milestones done collaborations with pharmaceutical partners.